Pariser D, et al. - This research encompassed a comparative investigation of the safety and efficacy profile of secukinumab in North American (NA) vs non-NA patients with moderate to severe psoriasis. Variations were reported in the baseline characteristics. However, findings illustrated similar efficacy and safety profile of secukinumab, among NA and non-NA patients.

Methods

• Data extraction was conducted from four phase 3 studies of secukinumab.
• As a part of this study, secukinumab (300 and 150 mg) was administered at baseline, weeks 1, 2, and 3, then every 4 weeks from week 4 to 48.

Results

• Findings displayed peak efficacy at week 16 in NA and non-NA patients with secukinumab 300 mg and secukinumab 150 mg.
• The disease clearance was maintained to week 52.
• Psoriasis Area and Severity Index (PASI) 90/100 response was achieved by 62.9%/37.9% of NA patients, respectively, and 70.2%/42.0% of non-NA patients, respectively, at week 52 with secukinumab 300 mg.
• It was noted that PASI 90/100 response was achieved by 30.9%/17.5% of NA patients, respectively, and 53.9%/26.9% of non-NA patients, respectively, at week 52 with secukinumab 150 mg.
• A rapid response to secukinumab was discovered.
• The results also illustrated the achievement of a 50% reduction in mean PASI in both groups, after 2.9 weeks with secukinumab 300 mg and 3.7 weeks with secukinumab 150 mg.